Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bayer AG is conducting a clinical study titled ‘An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation.’ The study aims to evaluate the safety and efficacy of BAY2927088, a drug designed to inhibit mutated EGFR and HER2 proteins, which are known to drive the growth and spread of NSCLC. The primary objectives are to determine the maximum tolerated dose and assess the drug’s pharmacokinetics and efficacy in reducing tumor size.
BAY2927088 is an oral drug being tested in different formulations to block the mutated proteins responsible for cancer progression. The study is focused on finding the optimal dose that is both safe and effective for further testing.
The study follows a non-randomized, sequential intervention model with no masking, primarily aimed at treatment. It includes four parts: dose escalation, backfill, dose expansion, and extension, each designed to refine the dosage and assess the drug’s effectiveness.
The study began on October 25, 2021, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 7, 2025, indicating ongoing progress in the study.
This study could significantly impact Bayer’s stock performance by potentially introducing a new treatment for NSCLC, a highly competitive market. Positive results could enhance investor sentiment, especially given the lack of effective treatments for EGFR and HER2 mutations in NSCLC.
The study is ongoing, and further details are available on the ClinicalTrials portal.